ImmunoCellular Therapeutics, Ltd Completes Enrollment of Phase II Trial of ICT-107 in Glioblastoma  
9/5/2012 9:44:50 AM

LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) announced today that the company has completed enrollment for its Phase II randomized, double-blinded, placebo-controlled, multi-center trial of its dendritic cell-based cancer vaccine ICT-107 for treatment of glioblastoma. A total of 278 patients at 25 participating sites have been enrolled in this trial, which was initiated in January 2011.